Abstract: The invention relates to two morphologically homogeneous forms of Famotidine [chemical name: N-sulfamoyl-3-(2-guanidino-thiazole-4-yl-methylthio)-propionamidine]. Said forms are prepared by selective crystallization or precipitation.

Abstract: The invention relates to two morphologically homogeneous forms of Famotidine [chemical name: N-sulfamoyl-3-(2-guanidino-thiazole-4-yl-methylthio)-propionamidine]. Said forms are prepared by selective crystallization or precipitation.

Abstract: The invention relates to novel compounds 1-oxa-2-oxo-8- of the formula (I), ##STR1## wherein X means oxygen or an >NR group, whereinR stands for hydrogen, a C.sub.1-12 alkyl, C.sub.3-6 cycloalkyl, carbocyclic C.sub.6-10 aryl or carbocyclic C.sub.6-10 aryl-C.sub.10-4 alkyl group, the latter two groups are optionally substituted on their aromatic moiety by one or more, same or different halogen(s), one or more C.sub.1-4 alkyl or C.sub.1-4 alkoxy group(s);R.sup.1 and R.sup.2 together represent a methylene group or, when X stands for an >NR group, wherein R is as defined above, one of R.sup.1 and R.sup.2 may represent a hydroxyl group whereas the other is a methyl group;R.sup.3 stands for hydrogen or a phenyl group optionally substituted by one or more halogen(s), one or more C.sub.1-4 alkyl or C.sub.1-4 alkoxy or hydroxyl group(s);R.sup.4 means hydrogen, one or more halogen(s), C.sub.1-4 alkyl, C.sub.

Abstract: The present invention relates to compounds of the general formula (I), ##STR1## wherein R.sub.1 stands for hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or nitro group;R.sub.2 means a C.sub.1-7 alkyl group optionally substituted by: a hydroxyl or oxo group; or an ester group containing 1 to 4 carbon atoms in the alkoxy moiety; or a C.sub.1-4 alkoxy, cyano, amino, C.sub.1-4 alkylamino, or dialkylamino group; or an acyl group containing 1 to 7 carbon atoms in the alkyl moiety; orR.sub.2 means an aryl-C.sub.1-7 alkyl group optionally bearing the substituents defined above for R.sub.2 in the alkyl chain and optionally substituted by halogen, nitro, C.sub.1-4 alkyl or alkoxy group in the benzene ring; orR.sub.2 represents an allyl, phenylallyl or phenylsulfonyl group, both latter groups optionally being substituted by halogen or a C.sub.1-4 alkyl group in the benzene ring; orR.sub.2 stands for a carbamoyl group substituted by one or two C.sub.1-4 alkyl group(s) or phenyl group on the nitrogen atom.

Abstract: The invention relates to a novel stereoselective process for the preparation of dihdyrolysergol from lysergol by hydrogenation in the presence of solvent and palladium catalyst applied on a carrier, which comprises hydrogenating lysergol in the presence of one or more aprotic solvent(s) containing tertiary nitrogen atom(s) and a palladium catalyst applied on activated carbon, and recovering the product obtained from the reaction mixture in a known manner.

Abstract: The invention relates to novel nitrogen- and sulfur-containing heterocyclic compounds of the formula (I), acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) ##STR1## Ar stands for an optionally mono- or polysubstituted aryl or heteroaryl group;R.sup.1 means a carbonyl or (C.sub.2-6 alkenyl)carbonyl group;R.sup.2 stands for hydrogen C.sub.1-6 alkyl, phenyl or phenyl (C.sub.1-4 alkyl) group;R.sup.3 means hydrogen or (C.sub.1-6 alkoxy)carbonyl group;R.sup.4 and R.sup.5 stand, independently from each other, for hydrogen or C.sub.1-6 alkyl group;R.sub.6 ogen, C.sub.1-6 alkyl group or halophenyl group;m is 0 or 1; andn is 1 or 2,with the proviso that R.sup.2 means hydrogen when m is 0.The compounds of formula (I) show a significant cerebral antihypoxic action and thus, they can be used for the treatment of diseases caused by hypoxic brain damages such as e.g.

Abstract: Peptides are disclosed which inhibit the immune system. The peptides are selected from the group consisting of:Arg-Lys(Chc)-Asp-ValArg-Lys(Chc)-AspArg-Sar-Asp-ValArg-Sar-AspOrn-Lys-Asp-ValOrn-Lys-AspArg-Lys-Aad-ValArg-Lys-Aad[Arg-Lys-Asp-NH-CH.sub.2 -].sub.2 ##STR1##Lys-Ser-Lys-LeuSer-Lys-LeuSer-Ser-Ser-ThrLys-Glu-ThrLys-Thr-Glu-ThrPro-Lys-Leu-ThrLys-Lys-Thr-Glu andLys-His-Leu-NH.sub.2,and pharmaceutically acceptable acid addition salts thereof.

Abstract: A Raney catalyst composition which has ice as a solid carrier. The reaction involving the Raney catalyst of the invention is carried out by portionwise adding a Raney catalyst containing ice as solid carrier to the reaction mixture. The operation-safe cylindrical or angular vessel used for the storage and/or handling of the Raney catalyst has a conical casing or side walls joining to the bottom through a bend radius of greater than 0.5 mm. The vessel is covered by a tightly closing cap.

Abstract: The invention relates to antiinflammatory compounds of the formula (I), ##STR1## wherein A stands for hydrogen, hydroxyl or trifluoroacetoxy group;X stands for hydrogen or halogen with the proviso that if A is hydrogen, then X also means hydrogen;R stands for hydrogen, benzoyl or C.sub.1-8 alkanoyl group; andrepresents a single or double bond between two adjacent carbon atoms,as well as pharmaceutical compositions containing these compounds and a process for their preparation.

Abstract: The invention relates to a novel cosmetic and paramedicinal active ingredient composition, particularly with an antiinflammatory and skin-calming effect, which comprises0.005 to 5.0% by weight of an aqueous-ethanolic extract of Marigold,0.005 to 2.0% by weight of an aqueous-ethanolic extract of Horse-chestnut0.005 to 2.0% by weight of an aqueous-ethanolic extract of Licorice (sweet-root),0.005 to 2.0% by weight of an aqueous Silver-weed extract,0.005 to 2.0% by weight of an aqueous extract of Walnut-tree leaves,0.002 to 1.0% by weight of Lavender resinoid and0.001 to 0.2% by weight of Roman camomile oilas calculated for the total weight; as well as85 to 99% by weight of a 35 to 60% by weight ethanol-water mixture as carrier.The above preparation serves as a base material for excellent cosmetic compositions, curative cosmetics and curative products.

Abstract: The invention relates to antiinflammatory compounds of the formula (I), ##STR1## wherein A stands for hydrogen or hydroxyl group;X stands for hydrogen or halogen with the proviso that if A is hydrogen, then X also means hydrogen;R stands for hydrogen, benzoyl or C.sub.1-8 alkanoyl group;R.sup.1 and R.sup.2, which are the same or different, stand for hydrogen or a C.sub.1-4 alkyl group; or one of R.sup.1 and R.sup.2 is hydrogen and the other is phenyl group; or R.sup.1 and R.sup.2 together form a C.sub.4-5 alkylene group;means a single or double bond between two adjacent carbon atoms,as well as pharmaceutical compositions containing these compounds and a process for their preparation.

Abstract: The invention relates to a stuffing box for the sealed passage of a shaft with undesirable deflection through connecting branch, provided with a casing, a stuffing box sland containing packing rings, as well as with a tubular spring compensator, one end of which is rigidly and releasably engaged with the connecting branch, the other end with the casing of the stuffing box. At least one guide bush (10) is arranged in the casing (8) centering the stuffing box (7) to the shaft (2). This guide bush can be arranged between the packing rings (9, 9a) and over (11) of the casing, and it is made of material, suitably of bearing material with low friction coefficient.

Abstract: The new peptides of the Formulae(1) Glp-Lys-NH.sub.2(2) Glp-Glu-Lys-NH.sub.2(3) Arg-Lys-Glu-NH.sub.2(4) Arg-lys-Asp-NH.sub.2(5) Arg-Lys-Glu-OH(6) Arg-Lys-Gln-OH(7) Leu-Val-Ala-OH(8) Arg-Orn-Asp-Val-NH.sub.2(9) Arg-Orn-Asp-Val-OH(10) Lys-Glu-Lys-Lys-OH(11) Lys-Leu-Lys-Lys-OH(12) Lys-Asp-Leu-Lys-OH(13) Glu-Leu-Val-Ala-OH and(14) Leu-Pro-Ala-Gly-OHand acid addition salts thereof inhibit the proliferation of leukaemic cells and exhibit immunostimulant effect.

Abstract: The present invention relates to novel compounds of the formula (I), ##STR1## wherein R.sub.1 and R.sub.2 stand independently from each other, for hydrogen, C.sub.1-4 alkyl, phenyl, phenyl-C.sub.1-4 alkyl, piridyl or piridyl-C.sub.1-4 alkyl group;E means a straight or branched, saturated hydrocarbon chain containing 1 to 6 carbon atoms;R.sub.3 represents: a phenyl group ortho-substituted by a C.sub.2-5 alkanoylamino, N-C.sub.2-5 alkanoyl-N-C.sub.1-4 alkylamino or di(C.sub.1-4 alkyl)amino group and optionally further substituted by halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or C.sub.2-5 alkanoyloxy group; or a pyridyl group optionally mono- or polysubstituted by halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-5 alkanoyloxy or phenyl-C.sub.1-4 alkoxy groupas well as their acid addition salts and tautomeric forms of these compounds.

Abstract: The invention relates to a process for the conversion of corrinoids produced by microorganisms into cyanocorrinoids by reaction with cyanides. According to the invention a fermentation broth obtained by disruption of microorganism cells in a known manner, preferably by heat treatment in the presence or absence of sulfite ions, optionally after purification steps known per se, is contacted with a suitable adsorbent or ion exchange resin, the corrinoids adsorbed on the surface of the adsorbent or ion exchange resin are treated with an aqueous solution containing cyanide ions or a compound capable of supplying cyanide ions, in an amount providing cyanide ions in a 1.1 to 2.0-fold molar excess related to the corrinoids, the adsorbent or ion exchange resin is washed with water, and the cyanocorrinoids obtained is eluted in a known manner, preferably with aqueous ethanol.

Abstract: Novel acrylic acid salts of formula ##STR1## wherein R represents a hydrogen or a halogen atom, a C.sub.1-4 alkyl, a C.sub.1-4 alkoxy or a nitro group,M represents a cation derived from bismuth, zinc or a pharmaceutically acceptable organic base,X represents an inorganic anion,n is an integer of from 0 to 2,m is an integer of from 1 to 3,p is 0 or 1, andr is an integer of from 0 to 6having cytoprotective and antiulcer activities are provided. A process is also described for the preparation of said compounds.

Abstract: The invention relates to novel peptides and their acid addition salts, suppressing the function of the immune system, pharmaceutical compositions containing these peptides as well as to a process for preparing these peptides and compositions. The peptides are represented by formulae (1) to (16): ##STR1## The novel peptides are useful for the therapy of diseases where a decrease in the activity of the immune system is desirable.

Abstract: The invention relates to a process for the production of 9.alpha.-hydroxy-4-androstene-3,17-dione from natural sterols of plant or animal origin or from mixtures thereof by the submerged aerobic fermentation of an enzyme-deficient, sterol-de-grading microorganism in a nutrient medium containing utilizable carbon and nitrogen sources as well as mineral salts, and by isolating the product formed, which comprises transforming the sterol or sterol mixture with the culture of a 1,2-steroid-dehydrogenase deficient strain of new Mycobacterium roseum species which is able to degrade the side-chain of natural sterols, preferably with Mycobacterium roseum sp. nov. 1108/1 deposited at the National Collection of Agricultural and Industrial Microorganisms, Budapest, Hungary under the number NCAIM B (P) 000339, and by isolating and purifying the 9.alpha.-hydroxy-4-androstene-3,17-dione obtained.

Abstract: The present invention relates to a method of treating a gastric ulcer by administering a 2-thia-zolone of the formula (I), ##STR1## wherein X stands for --CN, --CONH.sub.2, --CO.sub.2 H or --CO.sub.2 R group, wherein R is a C.sub.1-5 alkyl group; andn is 0, 1 or 2, with the proviso, that when X stands for CO.sub.2 H, CO.sub.2 R, n is other than 0.

Abstract: An antifungal or anthelmintic method of treatment is disclosed which comprises the step of administering to a mammal in need of said treatment, a pharmaceutically effective amount of a compound of the Formula (I) ##STR1## wherein X is halogen, C.sub.1 to C.sub.6 alkoxy, or a group --NRR.sup.1 in which R and R.sup.1 are each hydrogen or C.sub.1 to C.sub.6 alkyl; andR.sup.2 is hydrogen, halogen, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkoxy, phenyl, phenylthio, or phenyl or phenylthio substituted by at least one halogen or amino substituent; or a pharmaceutically acceptable acid addition salt thereof.